Diametric Capital’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Diametric Capital's NBIX Position: Q2 2026 in Review
Diametric Capital opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 7,486 shares worth $1.26M. The stake represents 0.13% of the portfolio and ranks #165 among its holdings. This is a return to the name: Diametric Capital previously reported a position in NBIX as recently as Q2 2025.
Diametric Capital first reported a position in NBIX in Q1 2025 and has held it in 3 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Diametric Capital held 7,486 shares of Neurocrine Biosciences worth $1.26M as of Q2 2026.
- Neurocrine Biosciences was a new Diametric Capital position in Q2 2026.
- Neurocrine Biosciences made up 0.13% of Diametric Capital's portfolio in Q2 2026, its #165 holding.
- Diametric Capital first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 3 quarters since.
- 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.